Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Jarrod P. Holmes, Jeremy D. Gates, Linda C. Benavides, Matthew Timothy Hueman, Mark G. Carmichael, Ritesh Patil, Dianna Craig, Elizabeth A. Mittendorf, Alexander Stojadinovic, Sathibalan Ponniah, George E. Peoples

Research output: Contribution to journalArticle

Abstract

BACKGROUND. E75, a HER-2/neu-derived peptide, was administered as a preventive vaccine with granulocyte-macrophage-colony-stimulating factor (GM-CSF) in disease-free lymph node-positive (NP) and lymph node-negative (NN) breast cancer (BCa) patients. The optimal biologic dose (OBD) was determined based on toxicity and immunologic response. METHODS. Patients were vaccinated over 6 months (3, 4, or 6 times) with different doses of E75 plus GM-CSF. Toxicities were graded per National Cancer Institute Common Terminology Criteria. GM-CSF was reduced for significant toxicity. Immunologic response was measured by delayed type hypersensitivity test (DTH), and E75-specific CD8 + T-cells were quantified with human leukocyte antigen-A2: immunoglobulin G dimer and flow cytometry. RESULTS. Ninety-nine patients (48 NP and 51 NN) were vaccinated in 7 dose groups. The OBD was 1000 lg E75 plus 250 μg GM-CSF monthly x 6. The optimal dose group (ODG, n = 29) experienced similar toxicities to the suboptimal dose group (SDG, n = 70), which was comprised of the remaining 6 groups. The ODG demonstrated a trend toward an increase in the average postvaccine dimer (0.87 ± 0.10% vs 0.67 ± 0.05%; P = .07), a significantly larger DTH response (21.5 ± 2.5 mm vs 11.3 ± 1.3 mm; P = .0002), and a trend toward decreased recurrences (3.4% vs 12.9%; P = .27). Compared with the SDG, the ODG had larger tumors (percentage ≥T2: 55% vs 23%; P = .004), more positive lymph nodes (percentage NP: 76% vs 37%; P = .001), and higher grade tumors (percentage grade 3: 52% vs 30%; P = .07), but a shorter median follow-up time (20 months vs 32 months; P

Original languageEnglish (US)
Pages (from-to)1666-1675
Number of pages10
JournalCancer
Volume113
Issue number7
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Fingerprint

Subunit Vaccines
Granulocyte-Macrophage Colony-Stimulating Factor
Appointments and Schedules
Clinical Trials
Breast Neoplasms
Recurrence
Lymph Nodes
Delayed Hypersensitivity
Neoplasms
National Cancer Institute (U.S.)
HLA Antigens
varespladib methyl
Terminology
Flow Cytometry
Vaccines
Immunoglobulin G
T-Lymphocytes
Peptides

Keywords

  • Breast cancer
  • Dosing
  • E75
  • Peptide
  • Vaccine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence : From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. / Holmes, Jarrod P.; Gates, Jeremy D.; Benavides, Linda C.; Hueman, Matthew Timothy; Carmichael, Mark G.; Patil, Ritesh; Craig, Dianna; Mittendorf, Elizabeth A.; Stojadinovic, Alexander; Ponniah, Sathibalan; Peoples, George E.

In: Cancer, Vol. 113, No. 7, 01.10.2008, p. 1666-1675.

Research output: Contribution to journalArticle

Holmes, JP, Gates, JD, Benavides, LC, Hueman, MT, Carmichael, MG, Patil, R, Craig, D, Mittendorf, EA, Stojadinovic, A, Ponniah, S & Peoples, GE 2008, 'Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02', Cancer, vol. 113, no. 7, pp. 1666-1675. https://doi.org/10.1002/cncr.23772
Holmes, Jarrod P. ; Gates, Jeremy D. ; Benavides, Linda C. ; Hueman, Matthew Timothy ; Carmichael, Mark G. ; Patil, Ritesh ; Craig, Dianna ; Mittendorf, Elizabeth A. ; Stojadinovic, Alexander ; Ponniah, Sathibalan ; Peoples, George E. / Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence : From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. In: Cancer. 2008 ; Vol. 113, No. 7. pp. 1666-1675.
@article{f05686bbf7664d688a352b3c484ad1a5,
title = "Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02",
abstract = "BACKGROUND. E75, a HER-2/neu-derived peptide, was administered as a preventive vaccine with granulocyte-macrophage-colony-stimulating factor (GM-CSF) in disease-free lymph node-positive (NP) and lymph node-negative (NN) breast cancer (BCa) patients. The optimal biologic dose (OBD) was determined based on toxicity and immunologic response. METHODS. Patients were vaccinated over 6 months (3, 4, or 6 times) with different doses of E75 plus GM-CSF. Toxicities were graded per National Cancer Institute Common Terminology Criteria. GM-CSF was reduced for significant toxicity. Immunologic response was measured by delayed type hypersensitivity test (DTH), and E75-specific CD8 + T-cells were quantified with human leukocyte antigen-A2: immunoglobulin G dimer and flow cytometry. RESULTS. Ninety-nine patients (48 NP and 51 NN) were vaccinated in 7 dose groups. The OBD was 1000 lg E75 plus 250 μg GM-CSF monthly x 6. The optimal dose group (ODG, n = 29) experienced similar toxicities to the suboptimal dose group (SDG, n = 70), which was comprised of the remaining 6 groups. The ODG demonstrated a trend toward an increase in the average postvaccine dimer (0.87 ± 0.10{\%} vs 0.67 ± 0.05{\%}; P = .07), a significantly larger DTH response (21.5 ± 2.5 mm vs 11.3 ± 1.3 mm; P = .0002), and a trend toward decreased recurrences (3.4{\%} vs 12.9{\%}; P = .27). Compared with the SDG, the ODG had larger tumors (percentage ≥T2: 55{\%} vs 23{\%}; P = .004), more positive lymph nodes (percentage NP: 76{\%} vs 37{\%}; P = .001), and higher grade tumors (percentage grade 3: 52{\%} vs 30{\%}; P = .07), but a shorter median follow-up time (20 months vs 32 months; P",
keywords = "Breast cancer, Dosing, E75, Peptide, Vaccine",
author = "Holmes, {Jarrod P.} and Gates, {Jeremy D.} and Benavides, {Linda C.} and Hueman, {Matthew Timothy} and Carmichael, {Mark G.} and Ritesh Patil and Dianna Craig and Mittendorf, {Elizabeth A.} and Alexander Stojadinovic and Sathibalan Ponniah and Peoples, {George E.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1002/cncr.23772",
language = "English (US)",
volume = "113",
pages = "1666--1675",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence

T2 - From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

AU - Holmes, Jarrod P.

AU - Gates, Jeremy D.

AU - Benavides, Linda C.

AU - Hueman, Matthew Timothy

AU - Carmichael, Mark G.

AU - Patil, Ritesh

AU - Craig, Dianna

AU - Mittendorf, Elizabeth A.

AU - Stojadinovic, Alexander

AU - Ponniah, Sathibalan

AU - Peoples, George E.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - BACKGROUND. E75, a HER-2/neu-derived peptide, was administered as a preventive vaccine with granulocyte-macrophage-colony-stimulating factor (GM-CSF) in disease-free lymph node-positive (NP) and lymph node-negative (NN) breast cancer (BCa) patients. The optimal biologic dose (OBD) was determined based on toxicity and immunologic response. METHODS. Patients were vaccinated over 6 months (3, 4, or 6 times) with different doses of E75 plus GM-CSF. Toxicities were graded per National Cancer Institute Common Terminology Criteria. GM-CSF was reduced for significant toxicity. Immunologic response was measured by delayed type hypersensitivity test (DTH), and E75-specific CD8 + T-cells were quantified with human leukocyte antigen-A2: immunoglobulin G dimer and flow cytometry. RESULTS. Ninety-nine patients (48 NP and 51 NN) were vaccinated in 7 dose groups. The OBD was 1000 lg E75 plus 250 μg GM-CSF monthly x 6. The optimal dose group (ODG, n = 29) experienced similar toxicities to the suboptimal dose group (SDG, n = 70), which was comprised of the remaining 6 groups. The ODG demonstrated a trend toward an increase in the average postvaccine dimer (0.87 ± 0.10% vs 0.67 ± 0.05%; P = .07), a significantly larger DTH response (21.5 ± 2.5 mm vs 11.3 ± 1.3 mm; P = .0002), and a trend toward decreased recurrences (3.4% vs 12.9%; P = .27). Compared with the SDG, the ODG had larger tumors (percentage ≥T2: 55% vs 23%; P = .004), more positive lymph nodes (percentage NP: 76% vs 37%; P = .001), and higher grade tumors (percentage grade 3: 52% vs 30%; P = .07), but a shorter median follow-up time (20 months vs 32 months; P

AB - BACKGROUND. E75, a HER-2/neu-derived peptide, was administered as a preventive vaccine with granulocyte-macrophage-colony-stimulating factor (GM-CSF) in disease-free lymph node-positive (NP) and lymph node-negative (NN) breast cancer (BCa) patients. The optimal biologic dose (OBD) was determined based on toxicity and immunologic response. METHODS. Patients were vaccinated over 6 months (3, 4, or 6 times) with different doses of E75 plus GM-CSF. Toxicities were graded per National Cancer Institute Common Terminology Criteria. GM-CSF was reduced for significant toxicity. Immunologic response was measured by delayed type hypersensitivity test (DTH), and E75-specific CD8 + T-cells were quantified with human leukocyte antigen-A2: immunoglobulin G dimer and flow cytometry. RESULTS. Ninety-nine patients (48 NP and 51 NN) were vaccinated in 7 dose groups. The OBD was 1000 lg E75 plus 250 μg GM-CSF monthly x 6. The optimal dose group (ODG, n = 29) experienced similar toxicities to the suboptimal dose group (SDG, n = 70), which was comprised of the remaining 6 groups. The ODG demonstrated a trend toward an increase in the average postvaccine dimer (0.87 ± 0.10% vs 0.67 ± 0.05%; P = .07), a significantly larger DTH response (21.5 ± 2.5 mm vs 11.3 ± 1.3 mm; P = .0002), and a trend toward decreased recurrences (3.4% vs 12.9%; P = .27). Compared with the SDG, the ODG had larger tumors (percentage ≥T2: 55% vs 23%; P = .004), more positive lymph nodes (percentage NP: 76% vs 37%; P = .001), and higher grade tumors (percentage grade 3: 52% vs 30%; P = .07), but a shorter median follow-up time (20 months vs 32 months; P

KW - Breast cancer

KW - Dosing

KW - E75

KW - Peptide

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=54049092448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049092448&partnerID=8YFLogxK

U2 - 10.1002/cncr.23772

DO - 10.1002/cncr.23772

M3 - Article

C2 - 18726994

AN - SCOPUS:54049092448

VL - 113

SP - 1666

EP - 1675

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -